Reaction profile
The FDA adverse-event record for oedema of the extremities (see also other socs for most applicable oedema)
585 FDA reports name oedema of the extremities (see also other socs for most applicable oedema), a high-volume reaction in the CVM extract (VeDDRA 518). Plate stamps and neighbourhood peers follow.
- #583 of 2,481
- by report volume (all reactions)
- 585
- reports citing this reaction
- 27.0%
- death-coded share
- Dog
- most-affected species
Release-over-release change
What changed in the latest FDA data snapshot
PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Oedema of the extremities (see also other SOCs for most applicable oedema) has 585 reports now versus 581 in that prior snapshot: 4 more (0.7%).
- Report change
- +4
- Death-coded reports
- +1
- Death-coded share
- −0.0 pts
This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.
Subscribe to Oedema of the extremities (see also other SOCs for most applicable oedema) changesFDA AER · VeDDRA plate
Code 518 VOL-MID
VOL-MID · DEATH-HOT · UPPER-Q · PHOTO-FINISH · SPECIES-DOG · DRUG-LEAD · DESK-WIDE · BOOK-FULL
- VOL-MID 585 reports
- DEATH-HOT 27.0%
- UPPER-Q #583/2481
- PHOTO-FINISH Recovery prolonged
- SPECIES-DOG Dog · 428
- DRUG-LEAD Carprofen · 92
- DESK-WIDE 20 breeds
- BOOK-FULL 8/8 fields
Nearest volume peer: Recovery prolonged (±0 reports)
Upper-third death-coded share drives the outcome stamps on this plate; volume band, corpus rank, and co-report peers follow. Not a clinical diagnosis.
High-volume neighbourhood around Oedema of the extremities
Upper-third volume poles plus nearest peers, not a full reaction corpus board reprint.
Oedema of the extremities (see also other SOCs for most applicable oedema): high death-coded share in the FDA AER plate
Signature read: 158 death-coded reports is a heavy tail count for Oedema of the extremities (see also other SOCs for most applicable oedema) in the CVM extract. Report volume is upper-third scale: 585 named reports in the openFDA extract. Death-coded share is upper-third: 158 of 585 reports (27.0% of named reports). Nearest volume peer: Recovery prolonged (±0 reports). Lead species Dog (428). Lead co-reported drug Carprofen (92).
Read these counts as reporting volume, not risk: per our methodology, A high death-coded share in FDA filings does not prove causation; co-reporting is voluntary temporal association only. Browse the full reactions index or the about page for how PlainBreed frames FDA CVM extracts.
Species Most Affected
Breeds Most Affected
Associated Drugs
Nationwide reactions with similar profiles
Two openFDA-derived peer sets for Oedema of the extremities (see also other SOCs for most applicable oedema), both floored at ≥50 reports so the neighborhoods stay in the advertised mass (the volume chart above is the unfloored photo-finish strip).
Similar report volume
Nearest other reactions by FDA report count (585 here).
Similar death-coded share
Nearest other reactions by death-coded share (27.0% here), distinct from the volume row.
What to do with this reaction
- Compare Oedema of the extremities's report profile against similar reactions nationwide. See similar reactions
- Read how death-coded share differs from a mortality rate before drawing conclusions. Understanding adverse events
- Browse the full reaction directory to compare report counts across reaction types. All reactions
A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.
Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025
Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →